GlobeNewswire

World Conference on Lung Cancer Monday Press Conference: Clinical Research Results and Gender Differences in Lung Cancer Survival

Del

TORONTO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- At today’s press conference at the International Association for the Study of Lung Cancer’s (IASLC’s) 19th World Conference on Lung Cancer (WCLC), conference co-president Dr. Andrea Bezjak, M.D., FRCPC, MSc, professor in the Departments of Radiation Oncology and Health Policy, Management and Evaluation at the University of Toronto and staff radiation oncologist at Princess Margaret Cancer Centre, summarized the wide-ranging study topics presented in today’s conference, from significant clinical research findings to gender differences in lung cancer survival.  

IMpower132 study shows atezolizumab in combination with carboplatin and pemetrexed improves survival in Stage IV non-squamous NSCLC
Recent findings from the IMpower132 study, presented by Vassiliki A. Papadimitrakopoulou, M.D., chief of the Section of Thoracic Medical Oncology at MD Anderson Cancer Center, demonstrate that the use of atezolizumab in combination with carboplatin as first-line therapy and pemetrexed as maintenance therapy improves progression-free survival (PFS) in patients with Stage IV non-squamous non-small cell lung cancer (NSCLC). 

Though survival data is not yet mature, preliminary results indicate an improvement in overall survival (OS) with the three-drug combination. These results are significant because they indicate that the historically poor median OS of 12 months found with current standard-of-care treatment options can be improved upon.

“The findings from IMpower132 indicate that the addition of atezolizumab to a backbone of carboplatin and pemetrexed chemotherapy provides better clinical efficacy than carboplatin and pemetrexed alone…offering a valuable treatment option that prolongs survival for patients with Stage IV non-squamous NSCLC,” said Dr. Papadimitrakopoulou.

Read the full press release here.

Entrectinib produced a clinically meaningful response in locally advanced or metastatic ROS1 fusion-positive NSCLC
Recent findings demonstrate entrectinib, an oral, potent and selective ROS1/NTRK/ALK tyrosine kinase inhibitor, produced a clinically meaningful and durable systemic response in patients with and without central nervous system (CNS) metastases, according to results presented today by Robert C. Doebele, M.D., Ph.D., of the Division of Medical Oncology at the University of Colorado.

The results comprised of an integrated analysis of three studies, ALKA, STARTRK-1 and STARTRK-2, and included 53 patients. The response rate was 77.4 percent, with median duration of response of 24.6 months. The median progression free survival was 26.3 months for patients without CNS metastases and 13.6 months for patients with CNS metastases. Entrectinib was tolerable with a manageable safety profile.

"The data look very exciting. The hope is that entrectinib could replace crizotinib as a first-line therapy against ROS1-positive NSCLC," said Dr. Doebele.

Read the full press release here.

Dr. Lucy Kalanithi, opening plenary speaker at the IASLC World Conference on Lung Cancer, examines how serious illness can create important sense of meaning for HCPs, caregivers and patients
The importance of having a professional and personal sense of meaning when dealing with serious illness, such as lung cancer, was the topic of today’s opening Plenary Session, “Patients First.” Speaker Lucy Kalanithi, M.D., offered a unique dual perspective as a physician and a caregiver who lost her young spouse to Stage IV lung cancer.  

“When you are a medical professional who works with an illness as serious as lung cancer, that challenge comes with an inherent opportunity to add value and a sense of meaning not only to your patients’ lives but also to your own,” said Dr. Kalanithi. “This profession is not just a job, it’s a calling.”

Dr. Kalanithi’s debut presentation at the WCLC, When Breath Becomes Air, shares the title of her husband’s number-one New York Times best-selling memoir, for which she wrote the epilogue.

Read the full press release here.

Study shows outdoor air pollution exposure significantly higher in women non-smokers with lung cancer than women smokers with lung cancer
Findings from a recent study, presented by Renelle L. Myers, British Columbia Cancer Agency, Vancouver, demonstrate that female lung cancer patients who have never smoked have significantly greater exposure rates to outdoor air pollution than female lung cancer patients with a history of smoking.

The results of the study showed median air pollution exposure of never-smoker cancer patients was more than double that of ever-smokers with lung cancer. Interestingly, never-smokers with the highest levels of ambient particulate matter exposure were 74 percent women.

“The results of this study underscore the importance of factoring outdoor air pollution into lung cancer development among women, particularly those who have never smoked,” said Myers. “Although long-term exposure to ambient particulate matter has been associated with an increased risk of developing lung cancer…there is currently no lung cancer screening risk prediction model that includes air pollution as an individual risk factor in its calculation.”

Read the full press release here.

Women with non-small cell lung cancers live longer than men, WCLC study shows
Women diagnosed with non-small cell lung cancers (NSCLC) live longer than their male counterparts, according to results of a SWOG study presented today by Kathy Albain, M.D., the Huizenga Family Endowed Chair in Oncology Research at Loyola University Chicago Stritch School of Medicine.

Dr. Albain and her SWOG team studied 981 patients newly diagnosed with Stage I, II, or III NSCLC and grouped them into four cohorts based on sex and smoking history. Regardless of smoking history or any other factor, women in the trial had significantly better overall survival (OS) rates compared to men. The analysis found that female never-smokers and female ever-smokers had significantly better OS compared to male never-smokers and male ever-smokers.

“Women with NSCLC live longer, even when we control for every factor that might influence survival in NSCLC, including tobacco and other exposures, lifestyle factors, disease stage, treatment, tumor biology and hormonal factors,” said Dr. Albain. “Additional study is needed to further investigate favorable survival for women in this population, and our large clinical trials need to be equally balanced for women.”

Read the full press release here.

Smoking cessation services widely accepted during lung cancer screenings
A recent study, presented by William Evans, M.D., FRCPC, professor emeritus, McMaster University Department of Oncology, and Clinical Advisor, Smoking Cessation, Cancer Care Ontario, found that smoking cessation services (SCS) offered at the time of lung cancer screening had a high acceptance rate by current smokers.

Of 808 individuals eligible for lung cancer screening, 63 percent were identified as current smokers. Of screen-eligible current smokers, 89 percent accepted hospital-based cessation counseling, and 88 percent of those who had a baseline low-dose computed tomography (CT) in the reporting period attended a hospital-based counselling session.

“It is important to seize the opportunity to discuss smoking cessation with those attending a screening program,” said Dr. Evans. “The motivation of the individuals coming in for screening, combined with the approaches taken by the nurse navigator, has made the program successful. By taking an empathetic approach, we’ve been able to help current smokers get the resources they need to help with their addiction to nicotine.”

Read the full press release here.

Livestreams of the daily press conferences are available here.

About the WCLC
The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated solely to lung cancer and other thoracic malignancies, attracting over 7,000 researchers, physicians and specialists from more than 100 countries. The conference will cover a wide range of disciplines and unveil research studies and clinical trial results. For more information, visit http://wclc2018.iaslc.org/. Follow the conference on social media with: #WCLC2018.

About the IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. You can also follow the IASLC on Twitter, Facebook, LinkedIn and Instagram.

Contacts:
Lisa Rivero
Vice President
lrivero@jpa.com| +1 617-657-1305

Becky Bunn, MSc
Public Relations Manager
Becky.Bunn@IASLC.org | +1 720-254-9509 

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Magna Announces Fourth Quarter and 2018 Results and Raises Quarterly Cash Dividend by 11%22.2.2019 11:00:00Pressemelding

Fourth Quarter 2018 Highlights Record fourth quarter sales of $10.1 billion up 5% from the fourth quarter of 2017 Cash from operations of $1.6 billion Returned $585 million to shareholders through share repurchases and dividends Raised quarterly cash dividend by 11% to $0.365 per share Full Year 2018 Highlights Record sales of $40.8 billion, up 12% from 2017 Record diluted earnings per share of $6.61, an increase of 13% Record cash from operations of $3.7 billion Returned approximately $2.3 billion to shareholders through share repurchases and dividends AURORA, Ontario, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Magna International Inc. (TSX: MG; NYSE: MGA) today reported financial results for the fourth quarter and year ended December 31, 2018. THREE MONTHS ENDED DECEMBER 31, YEAR ENDED DECEMBER 31, 2018 2017 (2) 2018 2017 (2) Reported Sales $ 10,137 $ 9,684 $ 40,827 $ 36,588 Income from operations before income taxes $ 607 $ 765 $ 2,951 $ 2,985 Net income attributable to Magna International I

IMImobile announces integration of WhatsApp Business solution into its enterprise cloud communications platform IMIconnect22.2.2019 10:37:00Pressemelding

The WhatsApp Business solution will be made available across its enterprise cloud communications platform IMIconnect allowing businesses to launch business-to-consumer communications on WhatsApp LONDON, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Global cloud communications software and solutions provider IMImobile PLC, today announced the integration of the WhatsApp Business solution into its enterprise cloud communications platform IMIconnect. The WhatsApp Business solution enables businesses to connect with over 1.5 billion users in a simple, reliable, and private way across 180 countries worldwide. As a WhatsApp Business solution provider, the IMIconnect platform will enable enterprises to seamlessly integrate the WhatsApp Business solution into their customer communications strategies, and drive engagement through intelligent and context-aware messaging. “We are excited to announce the integration of the WhatsApp Business solution today in our IMIconnect platform. We understand that today’s

Nordic Innovators Cloudstreet and Domos Partner to Deliver an End-to-End, Application-Aware 5G Experience to the Home22.2.2019 09:00:00Pressemelding

Cloudstreet’s carrier-grade API and Network Slicing platform with Domos’ Machine Learning Solution for home networks delivers intelligent connectivity out of the box Barcelona, Spain., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Finland’s Cloudstreet, the US-patented Network Slicing Company, and Norway’s Domos, a leader in Machine Learning technologies for the smart home, are pleased to announce that they have teamed up to create the industry’s first end-to-end, intelligent application and context-aware network slicing solution for home networks. The solution will be on display February 25-28 at the Mobile World Congress in Barcelona in Hall 5, stand 5C41. A perfect example of MWC’s aspirational theme, “Intelligent Connectivity”, the solution closes the loop on delivering a 5G experience to fixed wireless home networks. The combined technologies solve two key, last-mile problems that have plagued mobile-enabled home networks: 1) How to build application-awareness into the network without comprom

General Electric Company: Doc re. GE Files Form 8-K22.2.2019 08:00:00Pressemelding

FAIRFIELD, Conn., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Company General Electric Company ISIN US3696041033 Symbol London: GEC | Paris: GNE Headline Doc re: GE files Form 8-K February 21, 2019 On February 21, 2019, General Electric Company (the "Company") filed a Form 8-K with the U.S. Securities and Exchange Commission ("SEC"), which has been submitted to RNS. It is also available on the SEC's website at http://www.sec.gov and on the Company's website at https://www.ge.com/investor-relations/events-reports. http://www.rns-pdf.londonstockexchange.com/rns/8048Q_1-2019-2-21.pdf CONTACT: GE Jennifer Erickson +001 646 682 5620 jennifer.erickson@ge.com This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit

Northland Power Reports Full Year and Fourth Quarter 2018 Results22.2.2019 02:52:00Pressemelding

Results Reflect Successful Growth Strategy with Free Cash Flow per Share Up 30% and Adjusted EBITDA Up 17% TORONTO, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Northland Power Inc. (“Northland” or the “Company”) (TSX: NPI) today reported financial results for the three months and year ended December 31, 2018. “2018 was a significant year for Northland. We continued to operate safely and efficiently, achieving strong growth in free cash flow and adjusted EBITDA,” said Mike Crawley, President and Chief Executive Officer of Northland. “Construction of Deutsche Bucht project remains on time and on budget, and we also remain well-positioned for continued growth. Our expansion into Asia has gained further traction, with the first of the three Hai Long offshore wind projects securing all approvals and permits. The next step for this 300 MW project will be executing its PPA.” Highlights: 2018 Financial Results Sales increased 13% from $1.4 billion in 2017 to $1.6 billion and gross profit increased 17% t

NexusTours appoints Sham Ganiwalla as Business Development Director for Europe and Middle East21.2.2019 18:25:00Pressemelding

CANCUN, Mexico, Feb. 21, 2019 (GLOBE NEWSWIRE) -- NexusTours is pleased to announce that Sham Ganiwalla has joined the company as Business Development Director for the Europe and Middle Eastern markets. With a career spanning many years in tourism working for companies such as Tourico Holidays and Hotelbeds, Sham has extensive knowledge about different areas of the business, from product and marketing, to performance management and customer service. Reporting to Nadia Younes, Commercial Director Europe & MEAPAC, Sham will bring value to the development of Nexus' projects across the region. Rubén Gutiérrez, President Destination Services of Sunwing, commented, “The addition of Sham, will allow us to accelerate our commercial expansion in Europe and MEAPAC. We know that there are many travel partners that will value our expansion and positioning as regional leaders in destinations across America, our quality of service as “local experts”, as well as the ease of obtaining reservations thr